CARBOGEN AMCIS expands capacity for parenteral drug manufacturing
In France, on newly acquired land located 7 km from the existing site in Riom north of Clermont-Ferrand in Auvergne, construction have begun in January 2021 with a new, state-of-the-art facility dedicated to custom development and manufacturing of parenteral drug products.
This new state-of-the-art facility will allow for larger capacities to supply our customers with clinical batches for phase III clinical trials and small-scale for commercial. The handling of complex formulations will include a large range of APIs from biologics to highly potent compounds.
Operations will commence during Q1 of 2023.
If you would like to keep up with the progress of the site construction and look for more information, please visit our Knowledge Centre.
To download the Saint-Beauzire Fact Sheet, click on the link below
For more information
download our Drug Products
brochure or contact us today.
